Enzalutamide is Used for treating non-metastatic castration-sensitive prostate cancer patients with biochemical recurrence at high risk for metastasis. It was first introduced by Astellas Pharma Us Inc in its drug Xtandi on Aug 31, 2012. 5 different companies have introduced drugs containing Enzalutamide.
Enzalutamide Patents
Given below is the list of patents protecting Enzalutamide, along
with the drug name that holds that patent and the company name owning that
drug.
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Enzalutamide's patents.
Latest Legal Activities on Enzalutamide's Patents
Given below is the list recent legal activities going on the following
patents of Enzalutamide.
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on
Enzalutamide:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Several generic applications have been filed for Enzalutamide. The first generic version for Enzalutamide was by Actavis Laboratories Fl Inc and was approved on May 14, 2021. And the latest generic version is by Sandoz Inc and was approved on Apr 20, 2026.
Given below is the list of companies who have filed for
Enzalutamide generic, along with the locations of their manufacturing plants worldwide.
